This paper reports the diagnosis and treatment process of a patient with severe anemia caused by hookworm and Ascaris lumbricoides co-infections, so as to provide insights into clinical diagnosis and treatment and avoid misdiagnosis and under-diagnosis of parasitic infections. Living parasites were found by endoscopy, which were morphologically identified as hookworm and A. lumbricoides, and routine stool examinations detected hookworm and A. lumbricoides eggs. The patient was diagnosed with severe anemia caused by hookworm and A. lumbricoides co-infections by means of clinical symptoms, epidemiological history, endoscopic findings, and laboratory tests. Following blood transfusion, hemostasis, oral administration with albendazole, and symptomatic treatments, the patient showed remarkable symptomatic improvement and had a good prognosis.

The aim of this updated guideline is to provide comprehensive recommendations for the management of gout in patients with common comorbidities, such as chronic kidney disease(CKD), cardiovascular disease(CVD), diabetes, osteoarthritis(OA), and gastrointestinal disorders. This guideline was developed by a multidisciplinary expert panel consisting of specialists in endocrinology, rheumatology, nephrology, cardiology, gastroenterology, and methodology. The development process adhered to standard methodologies, including PICO(population, intervention, comparator, and outcomes) question deconstruction, systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation(GRADE) for evidence and recommendation evaluation, Delphi voting, and expert consensus. The guideline presents 26 evidence-based recommendations addressing 7 clinical questions for patients with hyperuricemia and gout in the context of comorbidities. Key recommendations include the maintenance of strict serum urate targets, particularly for patients with CKD stage≥3, chronic gouty arthritis, and OA, in order to prevent disease progression. In patients with CVD or diabetes, intra-articular triamcinolone is preferred over systemic glucocorticoids. Prioritized anti-inflammatory treatments for patients with CKD, gastrointestinal diseases and OA are recommended. The guideline also introduces emerging therapies, such as interleukin-1 inhibitors and selective urate transport inhibitors, as potential treatment options for refractory cases. The update offers a comprehensive, patient-centered approach to managing gout, particularly in individuals with associated comorbidities. Multidisciplinary collaboration and emerging new treatments and evidence ensure the optimization of the recommendations.

Objective:To analyze the endoscopic and clinicopathological characteristics of Helicobacter pylori ( HP)-negative early gastric cancer (EGC). Methods:A retrospective study was conducted on data of patients who were diagnosed as having EGC at the Affiliated Hospital of Qingdao University between June 2013 and March 2024. Cases meeting the diagnostic criteria for HP-negative status were included. Endoscopic findings and histopathological features of HP-negative EGC were systematically analyzed. Results:Among 698 EGC patients, 29 (4.2%) were identified as HP-negative. The age at diagnosis was 59.9±10.0 years, with marked female predominance (69.0%, 20/29 VS 31.0% males, 9/29). A body mass index ≥24 kg/m 2 was observed in 69.0% (20/29). Regarding therapeutic approaches, endoscopic submucosal dissection was performed in 89.7% (26/29). Among the 29 patients with a total of 30 lesions, the majority were localized to the middle third of the stomach (40.0%, 12/30), or the upper third (36.7%, 11/30). Differentiated-type accounted for 73.3% (22/30) among the histological types, including 13 oxyntic gland adenoma (OGA) / gastric adenocarcinoma of fundic-gland type (GA-FG) (upper third: 7; middle third: 6), and 2 gastric adenocarcinomas of fundic-gland mucosa type (GA-FGM) (both upper third). White-light endoscopy revealed polypoid or small submucosal tumor-like protrusions with whitish or erythematous discoloration and characteristic branching dilated vessels on the surface. Among the OGA/GA-FG lesions, 8 exhibited indistinct demarcation lines (DL). Additionally, both GA-FGM lesions demonstrated poorly defined DL. Three gastric adenocarcinomas of foveolar-type (GA-FV) were identified (upper/middle/lower third: 1 each), with 2 presenting as erythematous elevated masses. Five signet ring cell carcinomas (upper/middle/lower third: 1/3/1) exhibited flat or shallow depressed morphology with whitish or erythematous discoloration under white-light endoscopy; 3 exhibited well-demarcated borders. Four pyloric gland adenocarcinomas and three poorly differentiated tubular adenocarcinomas showed no significant differences in endoscopic features on white-light and narrow-band imaging compared to HP-positive EGC. No intestinal-type adenocarcinomas were identified. Conclusion:HP-negative EGC exhibit distinct endoscopic and clinicopathological characteristics, including female predominance and frequent differentiated histology, and upper/middle-third localization of elevated lesions, primarily OGA/GA-FG.

The aim of this updated guideline is to provide comprehensive recommendations for the management of gout in patients with common comorbidities, such as chronic kidney disease(CKD), cardiovascular disease(CVD), diabetes, osteoarthritis(OA), and gastrointestinal disorders. This guideline was developed by a multidisciplinary expert panel consisting of specialists in endocrinology, rheumatology, nephrology, cardiology, gastroenterology, and methodology. The development process adhered to standard methodologies, including PICO(population, intervention, comparator, and outcomes) question deconstruction, systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation(GRADE) for evidence and recommendation evaluation, Delphi voting, and expert consensus. The guideline presents 26 evidence-based recommendations addressing 7 clinical questions for patients with hyperuricemia and gout in the context of comorbidities. Key recommendations include the maintenance of strict serum urate targets, particularly for patients with CKD stage≥3, chronic gouty arthritis, and OA, in order to prevent disease progression. In patients with CVD or diabetes, intra-articular triamcinolone is preferred over systemic glucocorticoids. Prioritized anti-inflammatory treatments for patients with CKD, gastrointestinal diseases and OA are recommended. The guideline also introduces emerging therapies, such as interleukin-1 inhibitors and selective urate transport inhibitors, as potential treatment options for refractory cases. The update offers a comprehensive, patient-centered approach to managing gout, particularly in individuals with associated comorbidities. Multidisciplinary collaboration and emerging new treatments and evidence ensure the optimization of the recommendations.

Objective:To analyze the endoscopic and clinicopathological characteristics of Helicobacter pylori ( HP)-negative early gastric cancer (EGC). Methods:A retrospective study was conducted on data of patients who were diagnosed as having EGC at the Affiliated Hospital of Qingdao University between June 2013 and March 2024. Cases meeting the diagnostic criteria for HP-negative status were included. Endoscopic findings and histopathological features of HP-negative EGC were systematically analyzed. Results:Among 698 EGC patients, 29 (4.2%) were identified as HP-negative. The age at diagnosis was 59.9±10.0 years, with marked female predominance (69.0%, 20/29 VS 31.0% males, 9/29). A body mass index ≥24 kg/m 2 was observed in 69.0% (20/29). Regarding therapeutic approaches, endoscopic submucosal dissection was performed in 89.7% (26/29). Among the 29 patients with a total of 30 lesions, the majority were localized to the middle third of the stomach (40.0%, 12/30), or the upper third (36.7%, 11/30). Differentiated-type accounted for 73.3% (22/30) among the histological types, including 13 oxyntic gland adenoma (OGA) / gastric adenocarcinoma of fundic-gland type (GA-FG) (upper third: 7; middle third: 6), and 2 gastric adenocarcinomas of fundic-gland mucosa type (GA-FGM) (both upper third). White-light endoscopy revealed polypoid or small submucosal tumor-like protrusions with whitish or erythematous discoloration and characteristic branching dilated vessels on the surface. Among the OGA/GA-FG lesions, 8 exhibited indistinct demarcation lines (DL). Additionally, both GA-FGM lesions demonstrated poorly defined DL. Three gastric adenocarcinomas of foveolar-type (GA-FV) were identified (upper/middle/lower third: 1 each), with 2 presenting as erythematous elevated masses. Five signet ring cell carcinomas (upper/middle/lower third: 1/3/1) exhibited flat or shallow depressed morphology with whitish or erythematous discoloration under white-light endoscopy; 3 exhibited well-demarcated borders. Four pyloric gland adenocarcinomas and three poorly differentiated tubular adenocarcinomas showed no significant differences in endoscopic features on white-light and narrow-band imaging compared to HP-positive EGC. No intestinal-type adenocarcinomas were identified. Conclusion:HP-negative EGC exhibit distinct endoscopic and clinicopathological characteristics, including female predominance and frequent differentiated histology, and upper/middle-third localization of elevated lesions, primarily OGA/GA-FG.

Objective:To investigate the association of malnutrition based on Global Leadership Initiative on Malnutrition (GLIM) criteria with the disease activity and clinical outcomes in hospitalized ulcerative colitis (UC) patients.Methods:Clinical data of 115 patients with UC hospitalized in the Affiliated Hospital of Qingdao University from September 2019 to March 2023 were prospectively analyzed. GLIM and European Society for Clinical Nutrition and Metabolism (ESPEN) 2015 criteria were used for the diagnosis of malnutrition, allowing the analysis of consistency between two diagnostic criteria for malnutrition. The relationship between malnutrition based on GLIM criteria and disease activity and clinical outcome was further investigated. The risk factors of adverse clinical outcomes in UC patients were analyzed using binary logistic regression.Results:GLIM and ESPEN 2015 diagnostic criteria showed high correlation and consistency (AUC=0.875, P<0.001; K=0.809, P<0.001). According to GLIM criteria, the prevalence of malnutrition among hospitalized UC patients was 32.17% (37 cases). Compared with non-malnourished UC patients, the modified Mayo score and C-reactive protein level of malnutrition patients were higher ( P<0.005), and the proportion of patients with severe disease activity was higher ( P=0.005). UC patients in the malnourished group had longer hospital stay ( P<0.001), higher hospitalization costs ( P<0.001), and higher rates of drug escalation/conversion therapy, re-admission and surgery at 12 weeks and 54 weeks ( P<0.05). Binary logistic regression analysis showed that a high Mayo score ( OR=3.606, P=0.016), a high modified Mayo score ( OR=1.346, P=0.009) and malnutrition ( OR=1.430, P=0.012) were independent risk factors for adverse clinical outcomes of hospitalized UC patients at 12 weeks. A high modified Mayo score ( OR=6.491, P=0.011) and malnutrition as per GLIM criteria ( OR=6.693, P=0.033) were independent risk factors for adverse clinical outcomes of hospitalized UC patients at 54 weeks. Conclusions:GLIM and ESPEN 2015 diagnostic criteria show high consistency in the diagnosis of malnutrition in hospitalized UC inpatients. Malnutrition may imply adverse clinical outcomes of hospitalized UC patients, which is an independent risk factor for the adverse clinical outcome of hospitalized UC patients.

Objective:To investigate the efficacy and safety of linaclotide(LIN) combined with polyethylene glycol(PEG) for bowel preparation in patients with functional constipation (FC).Methods:From August 1, 2022 to April 30, 2023, a total of 300 patients with FC (FC group) and 300 subjects with non-functional constipation (NFC, NFC group) undergoing colonoscopy at the Affiliated Hospital of Qingdao University were selected. According to simple random sampling method, both FC group and NFC group were divided into 3 L PEG subgroup, 3 L PEG+ LIN subgroup, and 2 L PEG+ LIN subgroup, respectively, with 100 cases in each group and a total of 6 subgroups. All subjects were enrolled based on a random number table and received the corresponding bowel preparation protocols. The Ottawa bowel preparation score (OBPS) and the rate of adequate bowel preparation were calculated. Ordered logistic regression analysis was used to analyze the independent influencing factors of OBPS. The incidence of adverse events (such as bloating) and the repetition rate of regimen intention were analyzed. One-way ANOVA, least significant difference analysis, and chi-square test were used for statistical analysis.Results:The OBPS of the 3 L PEG subgroup, 3 L PEG+ LIN subgroup, and 2 L PEG+ LIN subgroup in the FC group were 6.06±1.67, 3.86±2.20, and 4.06±2.03, respectively, while the OBPS of the 3 corresponding subgroups in the NFC group were 5.08±1.92, 3.42±2.04, and 3.63±1.93, respectively. The OBPS scores of the 2 L PEG+ LIN and 3 L PEG+ LIN subgroups in FC and NFC group were lower than those of the 3 L PEG subgroup within the respective group, and the differences were statistically significant ( t=7.16, 7.55, 4.59, and 6.06; all P<0.001). The rates of adequate bowel preparation of the 3 L PEG subgroup, 3 L PEG+ LIN subgroup, and 2 L PEG+ LIN subgroup in the FC group were 83.0% (78/94), 95.6% (87/91), and 96.8% (92/95), respectively, while the rates of adequate bowel preparation of the 3 subgroups in the NFC group were 88.0% (88/100), 96.9%(94/97), and 97.0%(96/99), respectively. The rates of adequate bowel preparation of 2 L PEG+ LIN and 3 L PEG+ LIN subgroups in FC and NFC group were higher than those of the 3 L PEG subgroup in the respective group, and the differences were statistically significant( χ2=10.04, 7.64, 5.74, and 5.55, P=0.001, 0.008, 0.029, 0.029). The FC group was divided into 2 L PEG+ LIN compared to 3 L PEG+ LIN subgroup, as well as 3 L PEG+ LIN compared to 3 L PEG subgroup for ordinal logistic regression analysis, and the result showed that the bowel preparation regimen was an independent influencing factor for OBPS ( OR=0.940 and 3.072, 95% confidence interval 0.368 to 1.483 and 1.564 to 3.252; both P<0.001). The incidence of abdominal distension of the 3 L PEG subgroup in FC group and NFC group was higher than that of the 2 L PEG+ LIN subgroup in the respective group (11.7%(11/94) vs. 3.2%(3/95), 12.0%(12/100) vs. 4.0%(4/99)), and the differences were statistically significant( χ2=5.03 and 4.26, P=0.028 and 0.045). The repetition rates of regimen intention of the 2 L PEG+ LIN and 3 L PEG+ LIN subgroups in FC and NFC groups were higher than that of the 3 L PEG subgroup in respective group (93.7%(89/95), 93.4%(85/91) vs. 80.9%(76/94); 92.9%(92/99), 92.8%(90/97) vs. 82.0%(82/100)), and the differences were statistically significant ( χ2=5.25, 8.70, 4.31, and 5.40; P=0.009, 0.015, 0.020, and 0.023). Conclusions:The 2 L PEG+ LIN regimen can effectively decrease OBPS, improve qualified rate of bowel preparation and repetition rate of regimen intention, and reduce adverse events and the amount of fluid intake, in order to improve the tolerance and compliance of patients. Therefore, the 2 L PEG+ LIN regimen is recommended as a bowel preparation for colonoscopy in patients with FC.

Objective:To investigate the efficacy and safety of linaclotide(LIN) combined with polyethylene glycol(PEG) for bowel preparation in patients with functional constipation (FC).Methods:From August 1, 2022 to April 30, 2023, a total of 300 patients with FC (FC group) and 300 subjects with non-functional constipation (NFC, NFC group) undergoing colonoscopy at the Affiliated Hospital of Qingdao University were selected. According to simple random sampling method, both FC group and NFC group were divided into 3 L PEG subgroup, 3 L PEG+ LIN subgroup, and 2 L PEG+ LIN subgroup, respectively, with 100 cases in each group and a total of 6 subgroups. All subjects were enrolled based on a random number table and received the corresponding bowel preparation protocols. The Ottawa bowel preparation score (OBPS) and the rate of adequate bowel preparation were calculated. Ordered logistic regression analysis was used to analyze the independent influencing factors of OBPS. The incidence of adverse events (such as bloating) and the repetition rate of regimen intention were analyzed. One-way ANOVA, least significant difference analysis, and chi-square test were used for statistical analysis.Results:The OBPS of the 3 L PEG subgroup, 3 L PEG+ LIN subgroup, and 2 L PEG+ LIN subgroup in the FC group were 6.06±1.67, 3.86±2.20, and 4.06±2.03, respectively, while the OBPS of the 3 corresponding subgroups in the NFC group were 5.08±1.92, 3.42±2.04, and 3.63±1.93, respectively. The OBPS scores of the 2 L PEG+ LIN and 3 L PEG+ LIN subgroups in FC and NFC group were lower than those of the 3 L PEG subgroup within the respective group, and the differences were statistically significant ( t=7.16, 7.55, 4.59, and 6.06; all P<0.001). The rates of adequate bowel preparation of the 3 L PEG subgroup, 3 L PEG+ LIN subgroup, and 2 L PEG+ LIN subgroup in the FC group were 83.0% (78/94), 95.6% (87/91), and 96.8% (92/95), respectively, while the rates of adequate bowel preparation of the 3 subgroups in the NFC group were 88.0% (88/100), 96.9%(94/97), and 97.0%(96/99), respectively. The rates of adequate bowel preparation of 2 L PEG+ LIN and 3 L PEG+ LIN subgroups in FC and NFC group were higher than those of the 3 L PEG subgroup in the respective group, and the differences were statistically significant( χ2=10.04, 7.64, 5.74, and 5.55, P=0.001, 0.008, 0.029, 0.029). The FC group was divided into 2 L PEG+ LIN compared to 3 L PEG+ LIN subgroup, as well as 3 L PEG+ LIN compared to 3 L PEG subgroup for ordinal logistic regression analysis, and the result showed that the bowel preparation regimen was an independent influencing factor for OBPS ( OR=0.940 and 3.072, 95% confidence interval 0.368 to 1.483 and 1.564 to 3.252; both P<0.001). The incidence of abdominal distension of the 3 L PEG subgroup in FC group and NFC group was higher than that of the 2 L PEG+ LIN subgroup in the respective group (11.7%(11/94) vs. 3.2%(3/95), 12.0%(12/100) vs. 4.0%(4/99)), and the differences were statistically significant( χ2=5.03 and 4.26, P=0.028 and 0.045). The repetition rates of regimen intention of the 2 L PEG+ LIN and 3 L PEG+ LIN subgroups in FC and NFC groups were higher than that of the 3 L PEG subgroup in respective group (93.7%(89/95), 93.4%(85/91) vs. 80.9%(76/94); 92.9%(92/99), 92.8%(90/97) vs. 82.0%(82/100)), and the differences were statistically significant ( χ2=5.25, 8.70, 4.31, and 5.40; P=0.009, 0.015, 0.020, and 0.023). Conclusions:The 2 L PEG+ LIN regimen can effectively decrease OBPS, improve qualified rate of bowel preparation and repetition rate of regimen intention, and reduce adverse events and the amount of fluid intake, in order to improve the tolerance and compliance of patients. Therefore, the 2 L PEG+ LIN regimen is recommended as a bowel preparation for colonoscopy in patients with FC.

Objective:To evaluate the prevalence and related risk factors of new onset diabetes after chronic pancreatitis by meta-analysis.Methods:Chronic pancreatitis, diabetes, post pancreatitis diabetes, type 2 diabetes, type 3c diabetes, endocrine dysfunction, chronic pancreatitis, diabetes mellitus, post pancreatitis diabetes mellitus, endocrine efficiency, risk factors were used as keywords, and the network database such as the CNKI database, Wanfang, Weipu, Chinese Medical Journal Full Text, PubMed, Embase, Cochrane Library, Web of Science, and so on from the database establishment to January 2023 were searched. The prospective and retrospective cohort studies on new diabetes after chronic pancreatitis published were searched and retrieved, and the papers were screened and the quality were evaluated according to preset inclusion and exclusion criteria; and the important data were extracted. Review Manager 5.4 was used for meta-analysis.Results:22 papers were finally included, including 13 785 patients with chronic pancreatitis, of which 4 233 were patients with new onset diabetes. Meta-analysis showed that the incidence of new diabetes after chronic pancreatitis was 29% ( RD=0.29, 95% CI 26%-32%, P<0.0001), which increased and tended to be stable along with the disease course. Alcohol drinking, smoking, alcoholic chronic pancreatitis, pancreatic calcification, biliary stricture, male, conservative treatment, pancreatic cyst and older onset age were considered as risk factors for new diabetes after chronic pancreatitis, and endoscopic treatment was considered as protective factors. Conclusions:The incidence of new diabetes after the diagnosis of chronic pancreatitis is relatively high. Clinically, we can identify high-risk groups exposed to risk factors, and early intervention can reduce the incidence rate of new diabetes after chronic pancreatitis and improve the prognosis of patients.

Objective:To investigate the predictive value of systemic immune inflammation index (SII) for the overall survival of patients with pancreatic cancer by propensity score matching analysis.Methods:The clinical data of 457 patients with pancreatic cancer admitted to the Affiliated Hospital of Qingdao University from August 2000 to December 2019 were retrospectively analyzed. The age, gender, presence of jaundice, pancreatitis and diabetes, serum CA19-9, total bilirubin level, neutrophil count, platelet count, lymphocyte count in blood, presence of radical surgery, tumor TNM stage, tumor location and the like were recorded. The cut-off value of SII was determined by Youden index. The patients were divided into high and low SII groups accroding to the cut-off value. The propensity score matching was applied to reduce the selection bias of patients. Patients were 1∶2 matched and the caliper value was 0.1. The difference on overall survival between the two groups was compared. The prognostic factors were analyzed by univariate and multivariate Cox regression analysis. Kaplan-Meier was used to draw the overall survival curve to calculate the cumulative survival rate, and the differences between the curves were analyzed by Log-Rank test.Results:The cut-off value of SII was 765. There were statistically significant differences between the high SII group ( n=125) and the low SII group ( n=332) on the presence or absence of pancreatitis, the level of total bilirubin in blood, radical surgery, and TNM stage before the propensity score matching (all P value <0.05). After propensity score matching, there was no statistically significant difference between the high SII group ( n=113) and the low SII group ( n=182) on all the clinical parameters mentioned above except for CA19-9, indicating that the two groups were comparable. Univariate analysis showed that the level of CA19-9, SII, radical surgery and different TNM stage were all related to the overall survival of pancreatic cancer patients. Multivariate analysis showed that high CA19-9 level, high SII, no radical surgery, and worse TNM stage were independent risk factors for short overall survival, and high SII ( HR=1.882, 95% CI 1.446-2.450, P<0.001) was significantly associated with poor prognosis. The overall survival of patients with high SII was obviously shorter than the low SII group ( P<0.001), and the average survival time of patients with high and low SII were 8.86 and 11.38 months, respectively. Conclusions:SII is of great value in evaluating the overall survival of pancreatic cancer patients. Higher SII is associated with shorter overall survival.